<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962402</url>
  </required_header>
  <id_info>
    <org_study_id>VALB-1259</org_study_id>
    <nct_id>NCT01962402</nct_id>
  </id_info>
  <brief_title>Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study</brief_title>
  <official_title>Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lorcaserin is effective for weight
      reduction in patients with weight gain as a result of antipsychotic medications.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study</time_frame>
    <description>The primary objective of this study is to evaluate the effectiveness of lorcaserin for weight loss management in patients on an antipsychotic agent. Will monitor the weight of the patient for evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of glucose control</measure>
    <time_frame>At initial visit and at week 12 of the study</time_frame>
    <description>Will evaluate lab values for fasting blood glucose, Hemoglobin A1c, and fasting insulin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of cravings</measure>
    <time_frame>initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study</time_frame>
    <description>Using various questionnaires to evaluate cravings of various foods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of mood</measure>
    <time_frame>At initial visit, then at week 4 and week 12 of the study</time_frame>
    <description>Using standard questionnaires to evaluate mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of systolic blood pressure</measure>
    <time_frame>initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of diastolic blood pressure</measure>
    <time_frame>initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pulse</measure>
    <time_frame>initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of body-mass index (BMI)</measure>
    <time_frame>initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of waist circumference</measure>
    <time_frame>initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of cholesterol control</measure>
    <time_frame>At initial visit and at week 12 of the study</time_frame>
    <description>Will measure fasting cholesterol labs, which will include total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of electrolytes</measure>
    <time_frame>At initial visit and at week 12 of the study</time_frame>
    <description>Will monitor basic metabolic panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of liver</measure>
    <time_frame>At initial visit and at week 12 of the study</time_frame>
    <description>Will monitor liver enzymes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of blood count</measure>
    <time_frame>At initial visit and at week 12 of the study</time_frame>
    <description>Will monitor blood count</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Weight Gain</condition>
  <arm_group>
    <arm_group_label>Lorcaserin with intensive diet counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorcaserin</intervention_name>
    <description>Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.</description>
    <arm_group_label>Lorcaserin with intensive diet counseling</arm_group_label>
    <other_name>Belviq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive dietary counseling</intervention_name>
    <description>All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.</description>
    <arm_group_label>Lorcaserin with intensive diet counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Patients currently on atypical antipsychotics

          -  The patient's BMI is greater than or equal to 30 kg/m2 OR the patient's BMI is greater
             than or equal to 27 kg/m2 in the presence of at least one weight-related co-morbidity
             such as hypertension, type 2 diabetes mellitus, dyslipidemia, metabolic syndrome,
             obstructive sleep apnea, or degenerative joint disease such as osteoarthritis.

          -  Patient agreeable to follow up with provider at the scheduled appointments at week 1,
             week 2, week 4, week 8, week 12 and week 16 after initiation of medication.

        EXCLUSION CRITERIA:

          -  Pregnancy in women or breastfeeding

          -  The patient has greater than mild aortic valve regurgitation, or moderate to greater
             mitral valve regurgitation

          -  Known hypersensitivity to lorcaserin

          -  The patient is taking another weight loss medication concurrently

          -  Dementia

          -  Age less than 18 or greater than 65

          -  No recent substance abuse within 3 months

          -  No suicidal ideation within 3 months

          -  Unable to give informed consent, unless patient is conserved, then the conservator can
             provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susan Shakib, Pharm.D.</last_name>
    <phone>562-826-8000</phone>
    <phone_ext>4564</phone_ext>
    <email>susan.shakib@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Nguyen, MD</last_name>
    <phone>562-826-8000</phone>
    <phone_ext>3160</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Shakib, Pharm.D.</last_name>
      <phone>562-826-8000</phone>
      <phone_ext>4564</phone_ext>
      <email>susan.shakib@va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Charles Nguyen</investigator_full_name>
    <investigator_title>Psychiatrist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

